This article is a correction to:
Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
Maurizio Pompili- Department of Neuroscience, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy
A Corrigendum on
Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
By Pompili M. Front. Psychiatry 10:931. doi: 10.3389/fpsyt.2019.00931
The author wishes to disclose that in the last two years he has lectured and served on advisory board honoraria or engaged in clinical trial activities with Angelini, Lundbeck, Janssen, Otsuka, and Allergan.
The author apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: suicide, treatment outcome, relapse, adherence, prevention
Citation: Pompili M (2020) Corrigendum: Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics. Front. Psychiatry 11:101. doi: 10.3389/fpsyt.2020.00101
Received: 05 February 2020; Accepted: 06 February 2020;
Published: 27 February 2020.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2020 Pompili. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maurizio Pompili, bWF1cml6aW8ucG9tcGlsaUB1bmlyb21hMS5pdA==